Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 3,157 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aileron Therapeutics Inc | ALRN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.01 | 0.20% | 5.01 | 07:29:18 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.00 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 44 | 3,157 | - | 1.01 - 7.42 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:48:20 | 1 | US$ 4.79 | USD |
Aileron Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.43M | 4.89M | - | 0 | -27.33M | -5.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aileron Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALRN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.83 | 7.42 | 4.12 | 5.02 | 407,323 | -0.82 | -14.07% |
| 1 Month | 5.65 | 7.42 | 4.12 | 5.32 | 140,199 | -0.64 | -11.33% |
| 3 Months | 5.07 | 7.42 | 3.93 | 5.23 | 64,700 | -0.06 | -1.18% |
| 6 Months | 1.27 | 7.42 | 1.01 | 3.94 | 98,139 | 3.74 | 294.49% |
| 1 Year | 1.60 | 7.42 | 1.01 | 3.59 | 57,850 | 3.41 | 213.13% |
| 3 Years | 24.40 | 28.00 | 1.01 | 11.56 | 330,232 | -19.39 | -79.47% |
| 5 Years | 33.80 | 49.40 | 1.01 | 22.84 | 629,452 | -28.79 | -85.18% |
Aileron Therapeutics Description
| Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. |
